Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

1 Introduction Acute myeloid leukemia (AML) is a prevalent malignant myeloid tumor, predominantly occurring in elderly patients. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the ...

Fossil Records Reveal Forest Demise Fueled Ancient Climate Crisis How did ancient extinction events contribute to global climate change? This is what a recent study published in Nature Communications ...

The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01% ...

Invivoscribe's subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), has secured New York State (NYS) approval for the NPM1 MRD Assay, marking an advancement to combat acute ...

The NPM1 MRD Assay claims to deliver an ultra-sensitive DNA sequencing method to detect minimal residual leukaemia cells in those with nucleophosmin 1 (NPM1) mutation variants. Given that these ...

Add this topic to your repo To associate your repository with the flow-cytometry-data topic, visit your repo's landing page and select "manage topics." Learn more ...

NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01%, are ...